GM
82
2
GOOGL
72
13
FOXA
46
-2
VNO
44
-2
DGX
50
2
TXN
53
-2
EMN
73
-3
NTAP
64
-9
SYK
62
2
MMC
70
3
CVX
23
-2
UPS
55
4
APD
62
5
ALL
48
3
EL
59
3
PH
67
-4
ACN
38
-2
MRO
40
-2
PG
63
2
TJX
62
3
GM
82
2
GOOGL
72
13
FOXA
46
-2
VNO
44
-2
DGX
50
2
TXN
53
-2
EMN
73
-3
NTAP
64
-9
SYK
62
2
MMC
70
3
CVX
23
-2
UPS
55
4
APD
62
5
ALL
48
3
EL
59
3
PH
67
-4
ACN
38
-2
MRO
40
-2
PG
63
2
TJX
62
3
Financhill
Back

Janux Therapeutics 10K Form

Sell
37

JANX
Janux Therapeutics

Last Price:
47.03
Seasonality Move:
8.69%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive JANX News And Ratings

See the #1 stock for the next 7 days that we like better than JANX

JANX Financial Statistics

Sales & Book Value

Annual Sales: $8.08M
Cash Flow: $-15.03M
Price / Cash Flow: 0
Annual Sales: $12.65
Price / Book: 3.76

Profitability

EPS (TTM): -1.21000
Net Income (TTM): $-55.59M
Gross Margin: --
Return on Equity: -14.18%
Return on Assets: -12.93%

Janux Therapeutics Earnings Forecast

Key Janux Therapeutics Financial Ratios

  • The Research & Development expenses have been 679.48% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of JANX is -721.18% of Total Revenues.
  • Per Share Earnings over the last 5 years have been positive in 2 years.

Janux Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: JANX
Website: januxrx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 62.09
Quick Ratio: 61.85

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

JANX Technical Analysis vs Fundamental Analysis

Sell
37
Janux Therapeutics (JANX) is a Sell

Is Janux Therapeutics a Buy or a Sell?